Fig. 3
Treatment with the pyrophosphate analog etidronate rescues aspects of the dgf phenotype. (A) Measurements (in pixel area) of the mineralized area in the axial skeleton of Alizarin-Red- and Alcian-Blue-stained siblings (sibs; left panel) and mutants (right panel), which were either untreated (blue) or treated with 100 μM Etidronate (green). A2 indicates the region of interest that was measured for the analysis. No significant difference (ns) occurs in siblings (A,B left panels); in treated dgf mutants, the mineralized area was significantly reduced when compared with untreated dgf mutants (A,B right panels). n=50 (dgf 100 μM Etidronate); n=48 (dgf control); n= 24 (siblings 100 μM Etidronate); n=24 (siblings control).